Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D

ACC.25 – In STRIDE, the GLP-1RA semaglutide reduced maximal walking distance, symptoms and QoL in patients with PAD and T2D compared with placebo. “This represents a new therapeutic option for patients with PAD and T2D,” says Marc Bonaca.